T1	intervention 21 32	Balugrastim
T2	control 40 53	Pegfilgrastim
T3	eligibility 57 133	Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel
T4	No-of-participants 357 360	256
T5	outcome-Measure 599 646	duration of severe neutropenia (DSN) in cycle 1
T6	outcome-Measure 678 694	DSN (cycles 2-4)
T7	outcome-Measure 696 733	absolute neutrophil count (ANC) nadir
T8	outcome-Measure 735 760	febrile neutropenia rates
T9	outcome-Measure 766 799	time to ANC recovery (cycles 1-4)
T10	outcome-Measure 801 807	Safety
T11	outcome-Measure 809 825	pharmacokinetics
T12	outcome-Measure 831 845	immunogenicity
T13	outcome 861 877	Mean cycle 1 DSN
T14	outcome 1174 1205	time to ANC recovery in cycle 1
T15	outcome 1287 1314	Median terminal elimination
T16	outcome 1422 1439	Antibody response
T17	outcome 1570 1590	reducing cycle 1 DSN
